CN113117090A - 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 - Google Patents
以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 Download PDFInfo
- Publication number
- CN113117090A CN113117090A CN202110514957.8A CN202110514957A CN113117090A CN 113117090 A CN113117090 A CN 113117090A CN 202110514957 A CN202110514957 A CN 202110514957A CN 113117090 A CN113117090 A CN 113117090A
- Authority
- CN
- China
- Prior art keywords
- edema
- pharmaceutical composition
- osmotic pressure
- treating
- intracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110514957.8A CN113117090B (zh) | 2021-05-12 | 2021-05-12 | 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110514957.8A CN113117090B (zh) | 2021-05-12 | 2021-05-12 | 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113117090A true CN113117090A (zh) | 2021-07-16 |
CN113117090B CN113117090B (zh) | 2023-02-28 |
Family
ID=76781920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110514957.8A Active CN113117090B (zh) | 2021-05-12 | 2021-05-12 | 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113117090B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114632160A (zh) * | 2022-03-22 | 2022-06-17 | 南京中医药大学 | 一种治疗急性呼吸窘迫综合征肺水肿的药物组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108653305A (zh) * | 2018-05-18 | 2018-10-16 | 南京中医药大学 | 以胞内渗透压为靶点治疗脑水肿的药物组合 |
-
2021
- 2021-05-12 CN CN202110514957.8A patent/CN113117090B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108653305A (zh) * | 2018-05-18 | 2018-10-16 | 南京中医药大学 | 以胞内渗透压为靶点治疗脑水肿的药物组合 |
Non-Patent Citations (2)
Title |
---|
JIARUI ZHANG等: "Intracellular ion and protein nanoparticle-induced osmotic pressure modify astrocyte swelling and brain edema in response to glutamate stimuli", 《REDOX BIOLOGY》 * |
李宝嘉等: "依达拉奉联合尼莫地平对高血压脑出血患者血肿体积、脑水肿及血清人S100钙结合蛋白β、超敏C反应蛋白的影响", 《中国药物经济学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114632160A (zh) * | 2022-03-22 | 2022-06-17 | 南京中医药大学 | 一种治疗急性呼吸窘迫综合征肺水肿的药物组合物及其应用 |
CN114632160B (zh) * | 2022-03-22 | 2023-10-13 | 南京中医药大学 | 一种治疗急性呼吸窘迫综合征肺水肿的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113117090B (zh) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2146731B1 (en) | Cannabinoid-containing plant extracts for the treatment of prostate cancer | |
Tang et al. | Effects of dl-3-n-butylphthalide on serum VEGF and bFGF levels in acute cerebral infarction | |
EP2385835B1 (de) | Verwendung von deuteriumoxid zur behandlung viraler erkrankungen des auges | |
RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
WO2020187155A1 (zh) | 胡黄连素二聚体类似物衍生物在制备防治帕金森病的药物或保健品中的应用 | |
KR20190067219A (ko) | 통증 예방, 경감 또는 치료에서의 신경 흥분성 상해 관련 폴리펩타이드의 용도 | |
CN113117090B (zh) | 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用 | |
Zheng et al. | Engineered Multifunctional Zinc–Organic Framework-Based Aggregation-Induced Emission Nanozyme for Accelerating Spinal Cord Injury Recovery | |
Sosa Testé et al. | Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils | |
Park et al. | Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat | |
Gholamzadeh et al. | Intravenous injection of apelin-13 improves sensory-motor balance deficits caused by cerebral ischemic reperfusion injury in male wistar rats via restoration of nitric oxide | |
CN108014106A (zh) | 卡格列净在制备用于辅助治疗特发性肺纤维化的药物中的应用 | |
KR102606504B1 (ko) | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 | |
JP3415643B2 (ja) | 筋ジストロフィー症治療薬 | |
EP3102209A1 (en) | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system | |
Wang et al. | Naloxone combined with epinephrine decreases cerebral injury in cardiopulmonary resuscitation | |
AU2017206624A1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
CN108210879A (zh) | 一种治疗急性颅脑出血的药物组合物及其应用 | |
CN101516390B (zh) | 脑卒中后的反射性交感神经营养不良的发病预防剂 | |
RU2211703C2 (ru) | Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием | |
WO2022246595A2 (zh) | 一种抑制肿瘤相关成纤维细胞及调控肿瘤基质正常化的方法 | |
WO2023221793A1 (zh) | 一种酚酸衍生物用于治疗缺血性脑卒中的应用 | |
CN101496803B (zh) | 牛磺酸与安定复方在制备治疗缺血性脑损伤疾病的药物中的应用 | |
RU2655763C2 (ru) | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций | |
WO2019135363A1 (ja) | 腱滑膜病変を主体とした疾患の治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Jun Inventor after: Di Dong Inventor after: Qin Simiao Inventor after: Zheng Zihui Inventor after: Qian Zhizhi Inventor after: Chen Jiahui Inventor after: Qiu Huimin Inventor before: Di Dong Inventor before: Guo Jun Inventor before: Qin Simiao Inventor before: Zheng Zihui Inventor before: Qian Zhizhi Inventor before: Chen Jiahui Inventor before: Qiu Huimin |
|
GR01 | Patent grant | ||
GR01 | Patent grant |